Abstracts | 47 scores. A linear regression analysis revealed that being male and married had significant positive associations with sexual arousal, sexual satisfaction, and/or sexual desire, while the presence of TD and a longer duration of illness were associated with poor sexual arousal and/or sexual desire. Additionally, sexual function was significantly associated with SWN-K and DAI scores in multivariate analysis.
in switching group was significantly lower than that in addition group at week 8. Conclusion: Both addition and switching strategies were effective in resolving antipsychotics-induced hyperprolactinemia and hyperprolactinemia related adverse events including menstrual disturbances and sexual dysfunctions. These findings suggest that switching to aripiprazole may be more effective in normalizing hyperprolactinemia and improving hyperprolactinemia related adverse events in patients with schizophrenia.
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Abstract Background: The treatment of refractory schizophrenia is a great challenge. Clozapine is the only approved antipsychotics for refractory schizophrenia; however, its efficacy is unsatisfactory. Enhancing N-methyl-D-aspartate receptor (NMDAR) activation, including inhibition of D-amino acid oxidase (DAAO), has been reported to improve the clinical symptoms and cognitive function of patients with schizophrenia. This study examined the efficacy and safety of a DAAO inhibitor, sodium benzoate, for the treatment of refractory schizophrenia. Methods: We conducted a randomized, double-blind, placebocontrolled trial in four major centers in Taiwan. Sixty patients with refractory schizophrenia treated with clozapine were randomly allocated to sodium benzoate 1-g/d, sodium benzoate 2-g/d or placebo for a 6-weeks add-on therapy. The primary outcome measures including Positive and Negative Syndrome Scale (PANSS) total score, Scales for the Assessment of Negative symptoms (SANS), Quality of Life Scale (QOL) and Global Assessment of Function were assessed every two weeks. Results: Both sodium benzoate 1-g/d and 2-g/d produced better improvement than placebo in SANS (p = 0.024 and 0.027 at endpoint, respectively). Sodium benzoate 2-g/d also produced better improvement than placebo in PANSS total score and QOL (p = 0.005 and 0.008 at endpoint, respectively). However, sodium benzoate 2-g/d was not significantly better than 1-g/d in all primary and secondary outcome measures. Sodium benzoate was well tolerated without evident side-effects. Conclusions: Sodium benzoate adjuvant therapy significantly improved the negative symptoms of patients with refractory schizophrenia. The differences in efficacy domains between the two dose groups were insignificant. Key words: N-methyl-D-aspartate, refractory schizophrenia, D-amino acids oxidase (DAAO) inhibitor, sodium benzoate, clinical trial
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Urinary retention as a rare adverse effect of clozapine: a case report
Yi-Ting Lin National Taiwan University Hospital, Taiwan
Abstract Objective: Clozapine is a potent antipsychotics agent commonly prescribed for patients with refractory schizophrenia. However, it is also related to many troublesome adverse effects. For example, the common genitourinary adverse effects such as enuresis and urinary incontinence. Although clozapine is known for high anticholinergic activity, there has been only one case report about clozapine-related urinary retention in the literature. The aim of this study is to report a case of with clozapine-induced urinary retention and to discuss potential mechanisms. Methods: Case report. Results: We report a 19-year-old male patient of refractory schizophrenia who developed acute urinary retention during treatment with clozapine 200 mg/day and haloperidol 10 mg/ day. Urodynamic study suggested dysfunctional voiding. After a series of work-up, simplification of medications and dose adjustment, the urinary retention seemed to be resulted from
